CROs SIRO and AZIDUS Partner To Expand Their Services
Complete the form below to unlock access to ALL audio articles.
Clinpharm Private Limited, India’s earliest clinical research organization partners with Azidus, a full-service clinical research organization, to strategically expand combined services offerings and avail access to an expanded client base for technical requisites of pharmaceutical and biotechnology industries.
SIRO focuses on patient studies and support trials from Phase II to Phase IV, while Azidus is focused on healthy volunteer studies, bringing synergies to the collaboration. This partnership will help SIRO to expand its product range and get exclusive access to a larger pool of clients in potential geographies of Asia and Latin America, where Azidus has a strong base.
Commenting on the partnership, Akshay Daftary, Director in SIRO Clinpharm and in-charge of Global Business Development Activities and Client Management said, “The synergies of the service offerings of SIRO with Azidus are driven by a common belief in quality; the strategic alliance will serve a strong growth driver for both organizations. This is a complementary alliance which will give the clients single-window end-to-end solutions, with accrued cost benefits. This collaboration resonates strongly with the project growth initiative that we follow as SIRO’s vision. The alliance would definitely boost SIRO’s presence across geographies like Brazil in Latin America and the USA.”
Arjun Arumugam Olaganathan, Director, Azidus, said, “This strategic partnership with SIRO will help both organizations grow and expand their offerings. I see the potential of deeper market penetration and wider service contribution for the two organizations positively affecting their market values through this partnership. Both companies come with deep experience and a vision for excellence, which will also drive better service experience for clients”.
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
